Clinical trials: Coronary Stent Occlusion
Coronary Artery Disease, Coronary Stenosis
Reverse T-stenting and Minimal Protrusion With External Minicrush for Treatment of Complex Coronary Bifurcation
The Reverse T-stenting And Minimal Protrusion (Reverse TAP) is an up-front 2-stent technique that treats complex coronary bifurcation.
- Conditions
- Coronary Artery Disease, Coronary Stenosis, Coronary Disease
- Trial name
- T-REX (NCT05782738)
- Testing
- Percutaneous Coronary Intervention
- Where
- 5 sites in Italy
- Volunteers
- 361 people
- Sponsor
- San Luigi Gonzaga Hospital
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Hungary Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES)
- Trial name
- NCT01892917
- Where
- 13 sites in Hungary
- Volunteers
- 2,000 people
- Sponsor
- Biotronik Hungária Kft.
Coronary Artery Disease
Prospective, Randomized, Multicenter Study to Assess the Safety and Effectiveness of the Orsiro Sirolimus-eluting Stent
BIOFLOW-IV is a prospective, international, multicenter, randomised controlled trial. The purpose of this trial is to compare the Biotronik Orsiro drug eluting stent system with the Xience Prime / Xience Xpedition (Xience)drug…
- Trial name
- BIOFLOW-IV (NCT01939249)
- Testing
- Abbott Laboratories Xience, Biotronik Orsiro
- Where
- 45 sites in Australia, Belgium and 10 more
- Volunteers
- 585 people
- Sponsor
- Biotronik AG
Coronary Artery Disease
Retrospective Study of the Impact of Drug Eluting Stents
The purpose of this study is to determine whether the use of drug eluting stents is associated with higher rates of death, myocardial infarction, and major bleeding.
- Trial name
- NCT00487604
- Where
- United States
- Volunteers
- 9,800 people
- Sponsor
- Providence Health & Services
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-VIII All-comers Orsiro Mission Safety and Performance Registry
The BIOFLOW-VIII registry is a post-market clinical evaluation of the Orsiro Mission stent in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- BIOFLOW-VIII (NCT04555174)
- Testing
- Orsiro Mission DES
- Where
- 41 sites in France
- Volunteers
- 872 people
- Sponsor
- Biotronik AG
Coronary Artery Disease
Prospective Multicenter Registry of Hybrid Coronary Artery Revascularization Combined With Surgical Bypass and Percutaneous Coronary Intervention Using Everolimus Eluting Metallic Stents
This prospective multicenter registry evaluates the efficacy of hybrid coronary revascularization (HCR) combining coronary artery bypass surgery (CABG) and percutaneous coronary intervention (PCI) in the treatment of multivessel…
- Trial name
- NCT02894255
- Testing
- Coronary artery bypass grafting, Percutaneous coronary intervention
- Volunteers
- 100 people
- Sponsor
- Teikyo University
Left Main Coronary Artery Disease, Left Anterior Descending Coronary Artery Stenosis
Prospective Evaluation for Hybrid Cardiac Procedures
Multidisciplinary team-approach in order to offer personalized treatments represents the emerging mainstream in cardiovascular medicine.
- Conditions
- Left Main Coronary Artery Disease, Left Anterior Descending Coronary Artery Stenosis, Valve Disease, Heart, Carotid Stenosis
- Trial name
- PERHAPS (NCT05143671)
- Testing
- Coronary artery bypass grafting, Percutaneous coronary intervention, Surgical valve replacement
- Where
- Italy
- Volunteers
- 134 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Coronary Artery Stenosis, Coronary Artery Disease
Prophylactic Intra-coronary Adenosine to Prevent Post Coronary Artery Stenting Myonecrosis
Myocardial damage occurs in up to 40% of cases when sensitive biomarkers are measured after coronary artery stenting. Such events have been associated with poor outcomes both at 30 days and long term.
- Trial name
- NCT00612521
- Testing
- Adenosine
- Where
- Canada
- Volunteers
- 200 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Coronary Artery Disease
ComparisiOn of Neointimal coVerage betwEen ZES and EES Using OCT at 3 Months
This study try to 1) evaluate the neointimal coverage and malapposition at 3 month after new zotarolimus eluting stent (Endeavor resolute) and everolimus eluting stent (Xience) implantation and 2) compare them between ZES…
- Trial name
- COVER OCT-II (NCT01091740)
- Testing
- ZES resolute (Endeavor Resolute), EES (Xience)
- Where
- 2 sites in South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Ischemic Heart Disease, Stenotic Coronary Lesion
RESOLUTE China Registry:
To document the safety and overall clinical performance of the Resolute Zotarolimus-Eluting Coronary Stent System in a real-world patient population requiring stent implantation.
- Conditions
- Ischemic Heart Disease, Stenotic Coronary Lesion, Cardiovascular Diseases, Arteriosclerosis
- Trial name
- R-C Registry (NCT01243749)
- Where
- 6 sites in China
- Volunteers
- 1,800 people
- Sponsor
- Medtronic Vascular
Coronary Artery Disease, Coronary Stenosis
Ultrathin DES in Complex PCI Scenarios: the ULTRA a Multicenter Study
ULTRA is a multicenter, observational, retrospective registry, enrolling consecutive patients treated with ultrathin coronary DES (coronary stent with strut thickness < 70 um) for coronary bifurcation lesions, left main disease…
- Conditions
- Coronary Artery Disease, Coronary Stenosis, Stent Restenosis, Left Main Coronary Artery Disease
- Trial name
- ULTRA (NCT05205148)
- Testing
- Percutaneous coronary intervention with the following platforms: Orsiro; Mistent; BioMime; Supraflex Cruz
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- A.O.U. Città della Salute e della Scienza
Coronary Artery Disease, Atheroscleroses, Coronary
Long Term Follow-up of Comparison of Clopidogrel vs. Aspirin Monotherapy After Drug-eluting Stent Implantation
This is an retrospective extended study of a randomized clinical trial (The HOST-EXAM trial ClinicalTrials.gov Identifier: NCT02044250).
- Trial name
- HOST-EXAM-EX (NCT05567536)
- Testing
- Antiplatelet Agents
- Volunteers
- 5,530 people
- Sponsor
- Seoul National University Hospital
Coronary Artery Disease
Multislice CT Angiography of Coronary Bifurcations and Outcomes After Intervention
This is prospective, observational study, that will be conducted in two high-volume university interventional cardiology centers.
- Trial name
- NCT01943643
- Testing
- multislice CT angiography
- Where
- Serbia
- Volunteers
- 70 people
- Sponsor
- Clinical Hospital Center Zemun
Acute Coronary Syndrome, Acute Myocardial Infarction
ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS
The purpose of this study is to evaluate the safety of reducing dual antiplatelet therapy (DAPT) duration to 1 month after implantation of the everolimus-eluting cobalt-chromium stent (CoCr-EES) under the setting of acute…
- Conditions
- Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease, Percutaneous Coronary Intervention
- Trial name
- STOPDAPT-2 ACS (NCT03462498)
- Testing
- 1-months DAPT, 12-month DAPT
- Where
- Japan
- Volunteers
- 3,008 people
- Sponsor
- Kyoto University, Graduate School of Medicine
Coronary Artery Disease, Angioplasty, Transluminal, Percutaneous Coronary
Safety Study to Assess the FEasibility of Use of the TRYTON Bifurcation Coronary Stent System (SAFE-TRY)
To assess the safety and feasibility of the use of the Tryton bifurcation coronary stent system for the treatment of single de novo bifurcation lesions in native coronary arteries.
- Trial name
- SAFE-TRY (NCT01174433)
- Testing
- Tryton
- Where
- 6 sites in Italy
- Volunteers
- 241 people
- Sponsor
- University of Padova
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW III Asia Registry Orsiro Stent System
Cliflical evaluation of th' Orsiro LESS 10 diabetic subjects requiring coronary revasculariza t ion with Drug Eluting Stefl ts (DES) .880 subjects will be enrolled in this registry.
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01941290
- Where
- 19 sites in China, India and 3 more
- Volunteers
- 387 people
- Sponsor
- BIOTRONIK Asia Pacific Pte Ltd
Angina Pectoris, Coronary Artery Disease
A Safety Study of ABI-007 for In-Stent Restenosis
This trial will treat patients with a new chemotherapeutic medicine who have undergone a successful and uncomplicated de novo stent placement in up to two native coronary arteries.
- Trial name
- NCT00093223
- Testing
- Paclitaxel Nanoparticle Albumin Bound
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- Celgene
Coronary Artery Diseases
BIOFLOW-III UK Satellite Registry Orsiro Stent System
Clinical evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES). 500 subjects will be enrolled in this registry.
- Trial name
- NCT02257710
- Testing
- Orsiro
- Where
- 4 sites in United Kingdom
- Volunteers
- 500 people
- Sponsor
- Biotronik UK Ltd.
Coronary Artery Disease
Does Co-registration of OCT and Angiography Reduce Geographic Miss of Stent Implantation?
The purpose of this study is to determine whether co-registration of OCT and angiography reduce geographic miss defined as stent edge dissection or significant residual stenosis at stent edge after stent implantation during…
- Trial name
- NCT02671123
- Testing
- Coronary PCI with OCT with Co Registration, Coronary PCI with OCT without Co Registration
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- St. Francis Hospital, New York
Coronary Artery Disease, Cardiac Death
BioFreedom QCA Study in CAD Patients
This study aims to demonstrate that the BioFreedom™ Cobalt Chromium Drug Coated Stent is non-inferior to the market authorized BioFreedom™ Stainless Steel Stent with respective to efficacy and shows a similar safety profile.
- Conditions
- Coronary Artery Disease, Cardiac Death, Myocardial Infarction
- Trial name
- BioFreedomQCA (NCT03307213)
- Testing
- BioFreedom™ CoCr Biolimus A9™ stent, BioFreedom™ SS Biolimus A9™ stent
- Where
- 2 sites in Denmark, Spain
- Volunteers
- 200 people
- Sponsor
- Biosensors Europe SA